Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

Parving, Hans‐Henrik; M. Brenner, Barry; J.V. McMurray, John; de Zeeuw, Dick; M. Haffner, Steven; D. Solomon, Scott; Chaturvedi, Nish; Persson, Frederik; S. Desai, Akshay; Nicolaides, Maria; Richard, Alexia; Xiang, Zhihua; Brunel, Patrick; A. Pfeffer, Marc

doi:10.1056/nejmoa1208799

Public

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

Published in New England Journal of Medicine • Nov 3, 2012

Authors:

Hans‐Henrik Parving

Barry M. Brenner

John J.V. McMurray

Abstract

BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8...

Subject

Aliskiren

Type 2 diabetes

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!